Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity by Knight, J.R.P. et al.
 The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Access to the 
published online version may require a subscription. 
Link to publisher version: https://doi.org/10.1098/rsob.130130  
Citation:  Knight JRP, Allison SJ and Milner J (2013) Active regulator of SIRT1 is required for 
cancer cell survival but not for SIRT1 activity. Open Biology. 3: 130130. 
Copyright statement: © 2013 The Authors. This is an Open Access article distributed under the 
Creative Commons CC-BY license. 
 
 on March 27, 2018http://rsob.royalsocietypublishing.org/Downloaded from rsob.royalsocietypublishing.orgResearch
Cite this article: Knight JRP, Allison SJ,
Milner J. 2013 Active regulator of SIRT1 is
required for cancer cell survival but not for
SIRT1 activity. Open Biol 3: 130130.
http://dx.doi.org/10.1098/rsob.130130Received: 5 August 2013
Accepted: 25 October 2013Subject Area:
cellular biology/molecular biology
Keywords:
active regulator of SIRT1, regulation of SIRT1,
p53 acetylationAuthor for correspondence:
John R. P. Knight
e-mail: jk227@le.ac.uk†Present address: MRC Toxicology Unit,
University of Leicester, Leicester LE1 9HN, UK.
‡Present address: Institute of Cancer
Therapeutics, University of Bradford, Tumbling
Hill Street, Bradford BD7 1DP, UK.
Electronic supplementary material is available
at http://dx.doi.org/10.1098/rsob.130130.& 2013 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.Active regulator of SIRT1 is
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but not for SIRT1 activity
John R. P. Knight†, Simon J. Allison‡ and Jo Milner
Department of Biology, University of York, York YO10 5DD, UK1. Summary
The NADþ-dependent deacetylase SIRT1 is involved in diverse cellular pro-
cesses, and has also been linked with multiple disease states. Among these,
SIRT1 expression negatively correlates with cancer survival in both laboratory
and clinical studies. Active regulator of SIRT1 (AROS) was the first reported
post-transcriptional regulator of SIRT1 activity, enhancing SIRT1-mediated
deacetylation and downregulation of the SIRT1 target p53. However, little is
known regarding the role of AROS in regulation of SIRT1 during disease.
Here, we report the cellular and molecular effects of RNAi-mediated AROS
suppression, comparing this with the role of SIRT1 in a panel of human cell
lines of both cancerous and non-cancerous origins. Unexpectedly, AROS is
found to vary in its modulation of p53 acetylation according to cell context.
AROS suppresses p53 acetylation only following the application of cell dama-
ging stress, whereas SIRT1 suppresses p53 under all conditions analysed.
This supplements the original characterization of AROS but indicates that
SIRT1 activity can persist following suppression of AROS. We also demonstrate
that knockdown of AROS induces apoptosis in three cancer cell lines, indepen-
dent of p53 activation. Importantly, AROS is not required for the viability of
three non-cancer cell lines indicating a putative role for AROS in specifically
promoting cancer cell survival.2. Background
SIRT1 is the human homologue of the Sir2 deacetylase and has been studied
widely as a factor in human disease. Functionally, SIRT1 is able to regulate cel-
lular metabolism, epigenetic gene expression and multiple target proteins
important to the cellular response to stress [1]. Misregulation of SIRT1 is impli-
cated biochemically and genetically in diabetes and has been proposed as a
therapeutic target in neurodegeneration, osteoarthritis and cardiovascular dis-
ease [2–8]. SIRT1 also has a role in tumour suppression in non-transformed
cells via maintenance of genomic stability [9–11]. However, cellular and mol-
ecular studies have revealed a pleiotropic role for SIRT1 in cancer, as it acts
as a tumour promoter post-cancer formation [12,13].
Cellular analyses have implicated SIRT1 in tumour cell growth, and poor
prognosis in hepatocellular carcinoma [14–16]. Others have reported SIRT1 over-
expression in primary and murine studies of prostate cancer [17,18] and found a
requirement for SIRT1 for pro-survival signalling in oestrogen positive breast
cancer, where expression also correlates with poor prognosis [19,20]. SIRT1 is
also over-expressed and required for cell survival in pancreatic cancers [21,22],
has been implicated in the non-solid tumour chronic myelogenous leukaemia
[23,24] and suggested as an anti-cancer target for medulloblastoma [25,26].
At the molecular level, SIRT1 promotes tumour cell survival via inactivation
of key tumour suppressor proteins such as the transcription factors p53 [27,28]
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and the signalling phosphatase PTEN [32]. Acetylation of p53
at a number of residues, including the SIRT1 target site lysine
382 (lysine 379 in the mouse), is essential for transactivation
of genes required for cell cycle arrest and the induction of apop-
tosis [33]. Activation of these genes forms the p53-mediated
stress response and plays an important part in the role of p53
as a tumour suppressor. As such, reduction of p53 acetylation
by SIRT1 will contribute to reduced tumour suppression via
p53. Additionally, SIRT1 promotes the tumorigenic functions
of the proto-oncogenes c-Myc and N-Myc by modulating tran-
scriptional co-activation, phosphorylation and protein stability
[34–37]. Furthermore, SIRT1 has been linked to modulation of
cancer epigenetics via regulation of histone acetylation [38], and
may be enhanced by the altered metabolic status of many
cancer cells via its dependence uponNADþ as a coenzyme [39].
The regulation of SIRT1 also supports a role in tumour
growth and survival [40]. For example, N-Myc and c-Myc
complete positive feedback loops that promote SIRT1
expression and activity [35,36], and the negative regulator
of SIRT1 hypermethylated in cancer 1 (HIC1) is commonly
epigenetically repressed in cancer, allowing for an increase
in SIRT1 activity [41].
This study focuses on protein-level regulation of SIRT1 by
active regulator of SIRT1 (AROS; also known as RPS19BP1)
[42]. Despite being the first reported post-translational regu-
lator of SIRT1, little is known regarding the role of AROS
in the context of SIRT1-related disease. AROS directly binds
at a site (amino acids 114–217) distal to the SIRT1 catalytic
domain (amino acids 245–495), and via this interaction pro-
motes SIRT1 deacetylation activity [42,43]. AROS function
has been correlated with SIRT1 in regulation of the heat
shock transcription factor 1 (HSF1) [44,45]. AROS suppressed
HSF1 acetylation and increased its promoter occupancy and
target transcription, correlating with the role of SIRT1. How-
ever, it is not known whether SIRT1 requires AROS for all
activity; although AROS has been reported to promote
SIRT1 activity, it is possible that SIRT1 functions in the
absence of AROS in certain cellular contexts. In reconstituted
in vitro SIRT1 deacetylase assays using purified factors, SIRT1
is able to deacetylate p53 in the absence of AROS [46,47].
However, the contribution of AROS to SIRT1 deacetylase
activity in a more physiological setting has not been studied
in detail.
Supplementary to regulation of SIRT1, AROS also directly
associates with the ribosomal protein RPS19 [48]. Through
this interaction, AROS promotes the assembly of small ribo-
somal subunits, with depletion of the protein perturbing
ribosome biogenesis and limiting global protein synthesis [49].
Interestingly, AROS may also regulate protein synthesis via a
continued association with mature small ribosomal subunits
and the suppression of eIF2a phosphorylation at serine 51, a
key limiting step in the initiation of protein synthesis [49].
The initial characterization of AROS as a regulator of
SIRT1 found that AROS depletion reduced the viability
of the HCT116 cancer cell line [42]. Conversely, the viability of
HEK293 cells, of non-cancerous origin, was not affected by
knockdown of AROS [45]. This is consistent with AROS
cooperating with SIRT1 to determine cell fate—we previously
identified SIRT1 as a survival factor for epithelial cancer cell
lines, whereas SIRT1 was redundant for survival of cell lines
of non-cancerous origin [50]. Importantly, the role of AROS in
regulating both cancer and non-cancer cell fate has not beenaddressed by a dedicated study. We address this here by
using cell lines of both cancerous and non-cancerous origin
to explore the role of AROS in cell viability.3. Results and discussion
3.1. Active regulator of SIRT1 expression does not
correlate with SIRT1
We hypothesized that similar expression patterns of SIRT1 and
AROS would suggest a consistent regulatory relationship
between the two proteins. To assess this, we compared the
protein expression of SIRT1 and AROS across a panel of
human cell lines by western blot (figure 1a). AROS shows vari-
able expression across the panel, and does not correlate with
SIRT1 expression. Taking densitometry readings and plotting
values for SIRT1 against AROS for each cell line gives a
R2-value of 0.394, indicating this poor correlation (see elec-
tronic supplementary material, table S1). Taking an example,
AROS expression is comparable between the MCF10A and
MCF7 cell lines, whereas the expression of SIRT1 is more
than twice as great in the MCF7 line. These expression patterns
imply avariance in the SIRT1/AROS relationship.We also note
the higher expression of SIRT1 in the cancer cell lines compared
with the non-cancer cell lines (figure 1a).
We proceeded to analyse the function of AROS, using
SIRT1 function for comparison. To do this, both SIRT1 and
AROS were targeted by RNAi in parallel to knockdown of a
positive control mRNA, Lamin AC. RNAi against AROS
reduces its mRNA expression, such that it is not detectable
by qPCR in ARPE19 cells (figure 1b) and leads to depletion
of AROS protein (figure 1c). Both SIRT1 and Lamin AC
mRNA and protein are also effectively and specifically reduced
by siRNA transfection with the relevant siRNAs (figure 1b,c).
3.2. Active regulator of SIRT1 promotes cancer cell
line survival
We next analysed the roles of SIRT1 and AROS in cell line
viability, using RNAi in a panel of cell lines with defined ori-
gins (figures 2 and 3). Suppression of either SIRT1 or AROS
in three epithelial cancer cell lines results in an increase in
refringent cells, consistent with an induction of apoptosis,
along with a concomitant reduction in the adhered cell popu-
lation (figure 2a). Effective knockdown of AROS is confirmed
by western blotting in each cell line (figure 2b). The apoptotic
phenotype was quantified by flow cytometry for annexin V
positive and propidium iodide negative cells, which are sig-
nificantly induced following silencing of either SIRT1 or
AROS in each of the cancer cell lines (figure 2c). AROS knock-
down induces a 4.4-fold increase in apoptosis in the HCT116
cell line compared with mock-treated cells, with 2.7-fold and
3.1-fold induction seen in the HCT116 p53–/– and MCF7
lines, respectively. These values are comparable with the
apoptotic induction following silencing of SIRT1 in each
cell line (figure 2c). Co-knockdown of AROS and SIRT1 in
HCT116 cells results in a similar induction of apoptosis to
knockdown of each individually (see electronic supplemen-
tary material, figure S1a). This non-additive induction of
apoptosis could imply that AROS suppresses apoptosis via
its activation of SIRT1—loss of AROS cannot further reduce
01
2
3
4
5
6
HCT116 HCT116 p53–/– MCF7
SI
RT
1
A
RO
S
*
* ***
*
*
***
*
*
**
HCT116 HCT116 p53–/– MCF7
HCT116 p53–/– MCF7HCT116
mock AROS mock AROSmock AROS
co
n
tr
ol
m
o
ck
SI
RT
1
A
RO
S
co
n
tr
ol
m
o
ck
SI
RT
1
A
RO
S
co
n
tr
ol
15 kDa
37 kDa
(a)
(b)
(c)
m
o
ck
SI
RT
1 
siR
N
A
A
RO
S 
siR
N
A
siRNA
fo
ld
 a
po
pt
os
is 
in
du
ct
io
n
AROS
siRNA
b-actin
m
o
ck
Figure 2. AROS promotes cancer cell line survival. (a) Phase contrast micro-
graphs 48 h following targeting of AROS or SIRT1 in HCT116, p53 wild-type
and null ( p532/2), and MCF7 cancer cells. (b) Western blotting for AROS
protein following RNAi in each cell line with b-actin used as a loading con-
trol. Dashed lines within blots indicate removal of lanes from original
autoradiographs. (c) Quantification of apoptotic induction in each cancer
cell line following silencing of SIRT1 or AROS, including a ‘control siRNA’
that does not induce apoptosis (Lamin AC siRNA in HCT116 isogenic lines;
LDH-B siRNA in MCF7 cells). Values are expressed relative to mock transfec-
tion, set to 1.0. ***p, 0.001, ** p, 0.01.
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Figure 1. AROS expression in cancer and non-cancer cell lines. (a) Western
blotting for the expression of AROS and SIRT1 proteins across a panel of
cancer and non-cancer cell lines (see Materials and methods). b-actin is
used as a loading control. (b) Quantification of Lamin AC, SIRT1 and AROS
mRNA by qRT-PCR from total RNA extracted from ARPE19 non-cancer cells
72 h post-transfection. ***p, 0.001. (c) Western blotting for expression of
proteins targeted by RNAi in ARPE19 cells in parallel to (b). Equal loading
of protein is assessed using b-actin.
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single knockdown of each target induces maximal apoptosis,
and as such additive apoptosis upon co-knockdown was not
registered, or alternatively that knockdown of each target
converges on this induction of apoptosis via different routes.
Importantly, in each of the cancer cell lines targeting of a
control mRNA does not induce an increase in apoptosis, indi-
cating that AROS or SIRT1 suppression-induced apoptosis
was not the consequence of functional RNAi (figure 2c). An
independent siRNA, AROS 2 siRNA, induces a similar altera-
tion in phenotype in the HCT116 cells to the first AROSsiRNA (see electronic supplementary material, figure S1b).
A significant 2.3-fold increase in apoptosis is seen following
AROS 2 siRNA treatment, supporting the role for AROS in
HCT116 cancer cell line survival.
3.3. Active regulator of SIRT1 is redundant for
non-cancer cell line survival
The observation that AROS silencing induces apoptosis in
three cancer cell lines is consistent with SIRT1 requiring
AROS to promote survival. This led us to analyse the role
of AROS in non-cancer cells, where SIRT1 is not essential for
survival [50]. Suppression of either SIRT1 or AROS in
ARPE19, WI-38 and MCF10A cell lines does not greatly alter
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Figure 3. AROS is redundant for survival in non-cancer cell lines. (a) Phase
contrast micrographs 72 h following targeting of AROS or SIRT1 in ARPE19,
WI-38 and MCF10A non-cancer cells. (b) Western blotting for AROS protein
following RNAi in each cell line. b-Actin is used as a loading control.
(c) Quantification of apoptotic induction following targeting of SIRT1 and
AROS in non-cancer cells. Apoptosis following mock transfection is set to 1.0.
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AROS suppression by RNAi is comparable with the level
seen in the panel of cancer cell lines (figures 3b and 2b). Despite
the efficient knockdown, silencing of either SIRT1 or AROS
does not increase the number of apoptotic cells, measured by
flow cytometry, compared with mock treatment in each of
the non-cancerous cell lines (figure 3c).
These data indicate that AROS is required for the survival of
three human cancer lines, but is redundant for viability in three
cell lines of non-cancerous origins. Furthermore, AROS is able
to promote cancer cell survival in the absence of p53 expression,
demonstrated by apoptotic induction in the HCT116 p53–/2
line (figure 2c). Apoptotic induction is lower in these p53 null
cells compared with wild-type cells, perhaps indicating that
p53 facilitates apoptosis when expressed. Importantly, the
data for AROS correlate with the role of SIRT1 in all cell lines
analysed (figures 2 and 3 and [50]). These data also suggest
that targeting AROS in cancer may be of therapeutic benefit.3.4. Active regulator of SIRT1 does not influence
SIRT1 expression
The similarity in phenotype following AROS or SIRT1 knock-
down suggests similar function, and is consistent with SIRT1
activity being promoted by association with AROS [42]. Simi-
lar to the original report of AROS function, knockdown of
AROS does not alter SIRT1 protein expression in the panel
of cell lines analysed (figure 1c and figure 4), aside from a
slight decrease in SIRT1 expression in the MCF10A cell line
following AROS knockdown. AROS knockdown does not
negatively affect SIRT1 mRNA expression in the ARPE19
cell line (figure 1) or the other five cell lines analysed
(see electronic supplementary material, figure S2). Figure 4
illustrates SIRT1 silencing resulting in the phenotypes in
figures 2 and 3. To this point, the data presented correlate
with a role for AROS in promoting SIRT1 function at the cel-
lular level, despite differences in relative expression of the
proteins between cell lines. We next analysed the role of
AROS in the molecular function of SIRT1-deacetylation.
3.5. Active regulator of SIRT1 suppression of p53
acetylation is variable
The role of SIRT1 in promoting cancer cell survival has been
linked to the suppression of p53 [27,28,50]. We therefore
asked whether AROS suppresses p53 in HCT116 cancer
cells, by monitoring total and acetylated p53 levels by
western blot following RNAi against AROS, and SIRT1 for
comparison. Suppression of SIRT1 results in an induction of
both total and acetylated p53 (figure 5a, left panel). This is
due to disruption of a constitutive cycle of acetylation and
deacetylation of p53 at lysine residue 382 via loss of SIRT1
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stress. Equal loading was assessed using b-actin. Asterisk indicates non-specific bands. Dashed lines within blots indicate removal of lanes from original
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continues, leading to increased acetyl-p53 (K382Ac). Acety-
lation of p53 is essential for activation of the transcriptional
programme required for tumour suppression [33], and is
generally followed by accumulation of p53 protein.
Should AROS promote SIRT1 activity towards p53, we
would expect a similar increase in p53 acetylation following
AROS knockdown, as reported previously [42]. However,
we observe that targeting of AROS does not increase acetyl-
ated or total p53 levels compared with mock treatment
under normal cell growth conditions (figure 5, left panel).
Thus, under these conditions, AROS does not appear to be
required for p53 deacetylation, suggesting that SIRT1 is
able to suppress p53 when AROS expression is reduced. It
is possible that incomplete silencing of AROS allows partial
function and suppression of p53. However, the extent of
AROS suppression achieved through RNAi-induced cancer
cell apoptosis (figure 2), suggesting that a loss of AROS
function has occurred.
In the light of these differences between AROS and SIRT1,
we noted that the most conclusive previous data indicating a
suppressive role for AROS upon p53 were obtained where
p53 had been activated by the application of stress in the
form of etoposide and trichostatin A [42]. This treatment
induces DNA damage, and subsequently elevates p53 levels
([51,52] and electronic supplementary material, figure S3b).Reproducing this treatment here results in a modest increase
in p53 acetylation following AROS knockdown (figure 5,
middle panel). SIRT1 silencing following drug treatment mir-
rors the effect of silencing SIRT1 in the absence of stress, with
both total and acetylated p53 levels increased.
Given the moderate suppression of p53 by AROS follow-
ing etoposide and trichostatin A treatment, we assessed a
second form of p53-inducing stress, ultraviolet (UV-C)
irradiation (see electronic supplementary material, figure S3b).
A single dose of 10 J m22 was applied 24 h prior to harvesting
cells which had been pre-treated with siRNAs against SIRT1
or AROS 48 h prior to harvesting. Following UV-C stress,
knockdown of either AROS or SIRT1 results in a large increase
in both total and acetylated p53 (figure 5, right panel). The
extent of p53 acetylation is greater following SIRT1 knockdown,
but the correlation between SIRT1 and AROS knockdown is
consistent with AROS promoting SIRT1-mediated deacetyla-
tion of p53 [42]. Silencing of either SIRT1 or AROS following
etoposide and trichostatin A treatment or UV-C irradiation
induced an increase in apoptosis (see electronic supplementary
material, figure S3c).
Consistent with the findings of Kim et al. [42], we find that
overexpression of flag-tagged AROS protein under normal
cell growth conditions reduces p53 acetylation (figure 5c).
From this, it appears that AROS has the capacity to activate
SIRT1 in the absence of exogenous stress, even though
rsob.royalsocietypublishing.org
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basal conditions. However, it is important to contrast the
loss-of-function RNAi experiments in figure 5a with the
gain-of-function overexpression experiments in figure 5c.
Forced overexpression of AROS reveals the functions AROS
is able to carry out, whereas removal of AROS by RNAi indi-
cates the functions AROS is actually carrying out. In this
instance, it appears that AROS is able to suppress p53, but
under basal conditions is not doing so. Thus, in HCT116
cells, SIRT1 can continue to deacetylate p53 in the absence
of AROS under basal conditions.
3.6. SIRT1 and active regulator of SIRT1 have different
molecular functions
All together, these data indicate different molecular roles for
SIRT1 and AROS in the regulation of p53; SIRT1 deacetylates
p53 under all conditions analysed, whereas AROS suppres-
sion of p53 acetylation is dependent upon cell context. We
assume that the regulation of p53 by AROS occurs via
SIRT1, or conversely that the lack of regulation of p53 results
from a lack of activation of SIRT1.
To understand this further, we analysed p53 protein
following co-knockdown of AROS and SIRT1 (figure 5b).
Surprisingly, we found that co-knockdown reduced the acety-
lation of p53 compared with SIRT1 knockdown alone—lanes
2 and 4. Unexpectedly, this suggests that AROS may be able
to promote p53 acetylation when SIRT1 protein levels are
reduced. One possible explanation is that SIRT1 regulates
AROS protein and activity, reminiscent of the functional inter-
action SIRT1 shareswith its repressor DBC1 [53], and opposing
acetyl-transferase p300 [54]. While not fully understood at
present, this may add an extra layer of complexity to the
relationship between SIRT1, AROS and p53 that warrants
further investigation.
It is important to note that the reduction in p53 acetylation
following co-knockdown of AROS and SIRT1 compared with
SIRT1 alone does not correlate with a reduction in apopto-
sis; no difference in the level of apoptosis is seen between
the two conditions (see electronic supplementary material,
figure S2a). This, and the fact that SIRT1 and AROS suppress
apoptosis in HCT116 p532/2 cells (figure 2), is consistent
with SIRT1 and AROS enhancing cancer cell survival by
p53 independent routes. Furthermore, it suggests that AROS
may regulate cell survival via regulation of alternative SIRT1
targets. Future studies should analyse AROS regulation of
SIRT1 targets other than p53 in an effort to understandwhether
AROS acts as an on/off activator or perhaps more intricately
via direction of SIRT1 towards certain substrates.
3.7. Physiological implications of a variable SIRT1/active
regulator of SIRT1 relationship
Interestingly, our data indicate a potential mechanism by
which SIRT1 responds to environment cues linked to cell
damage. SIRT1 may only require AROS for suppression of
p53 after cellular stress. In vitro analyses of SIRT1 activity
lend support to this non-essential role for AROS in SIRT1
activity [46,47]. Given that AROS regulation of SIRT1 depends
on direct association,we note that the SIRT1–AROS interaction
has recently been described as weaker than SIRT1 interactions
with many other proteins [55]. These interactions werequantified from cells under basal conditions, with the potential
for changes in the SIRT1 interactome following stress not ana-
lysed. Future studies will aim to elucidate the interaction and
regulatory dynamics between SIRT1 and AROS.
It is possible that the variable role for AROS in p53 suppres-
sion represents relative substrate availability; following stress,
the abundance of p53 is increased, perhaps rendering SIRT1
more dependent upon AROS for p53 deacetylation (see elec-
tronic supplementary material, figure S3b). However, p53
appears to be induced to a greater extent by etoposide and tri-
chostatin A treatment than UV-C irradiation, yet regulation by
AROS is greater following UV-C irradiation (figure 5 and the
electronic supplementary material, figure S3b). The intra-
cellular response to these insults will differ, which could
account for the differing severity of the de-repression of p53 fol-
lowing AROS silencing. UV-C irradiation damages DNA,
RNA and protein constituents of the cell [56], whereas the
application of etoposide and trichostatin A will be restricted
toDNAdamage [51,52].We recently identifiedAROS as a ribo-
some associated protein, important for maintaining maximal
ribosome function [49]. Interestingly, the ribosome acts a hub
for both RNA and protein quality control within the cell
[57,58], provoking the possibility that the differences in regu-
lation of SIRT1 by AROS are linked to regulation of AROS
via its ribosomal association.
Abnormal ribosomebiogenesis has longbeendiscussed as a
marker for cancer, presumably owing to a need for increased
protein synthesis [59,60]. Targeting of ribosome biogenesis
could provide a means to target rapidly dividing cells without
mutagenic chemotherapeutics. Recently, a proof-of-concept
study analysed suppression of ribosome biogenesis for anti-
cancer therapy, showing excellent specificity against lymphoma
cells in vivo [61]. Interestingly, cancer cell death was not depen-
dent on reduced protein synthesis, but instead required p53
activation following nucleolar disruption. We have shown
here that AROS is able to suppress p53 in cells exposed to
stress, is required for cancer cell survival, and previously, that
AROS is required for ribosome biogenesis [49]. It remains to
be seen how these functions of AROS relate to each other, and
to cancer cell survival.4. Conclusion
We have demonstrated a cancer-specific role for AROS in the
regulation of survival in a panel of human cell lines. The data
suggest that AROS, as well as SIRT1, promotes survival in
cancer cells while being redundant for viability in non-cancer
cells. However, at the molecular level, the roles of SIRT1 and
AROS differ with respect to regulation of p53. We find evi-
dence supporting a suppressive role for AROS in regulation
of p53, as previously reported [42], but also that AROS function
can be suppressed with no effect on p53—which is the case
under basal conditions. This indicates that SIRT1 does not
require AROS as a physiological activator under all circum-
stances and leads to the conclusion that the positive role of
AROS in regulating SIRT1 can respond to stimuli. As well as
the variable suppression of p53 by AROS, this could have
implications in the regulation of further SIRT1 targets, which
may be regulated in a similar manner. It will be interesting to
assess whether AROS is able to regulate multiple SIRT1 targets
differently, suggesting that AROS has the capacity to act as a
stimulus responsive orchestrator of SIRT1 activity. With
rsob.roy
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neurodegeneration, greater understanding of its endogenous
regulation could also lead to opportunities for therapeutic
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Biol3:1301305. Material and methods
5.1. Cell culture and treatments
All cell lines were grown at 378C in a humidified atmosphere
supplemented with 5% CO2. HCT116 and HCT116 p53
2/2
epithelial colorectal adenocarcinoma cell lines were kindly
provided by Prof. Bert Vogelstein [62]. These and the MCF7
(breast epithelium—ATCC HTB22) cell line are of cancerous
origin. The ARPE19 (retinal pigmented epithelium—ATCC
CRL-2302 [63]), WI-38 (lung fibroblast—ATCC CCL-75) and
MCF10A (breast epithelium—ATCC CRL-10317) cell lines
are not of cancerous origin. Etoposide and trichostatin A
(Sigma) were used at 20 and 0.5 mM, respectively, for 6 h
prior to harvesting of cells [42]. UV-C exposure was at a flu-
ency of 2 J m2 s21 with a total exposure of 10 J m2 as
previously described [64]. SiRNA transfection and sequences
for lamin AC and SIRT1 were previously described [50].
AROS siRNA sense sequences: (i) 50-CCGUGUUCACCGA
GGAAGA-(dTdT)-30 and (ii) 50-GACCACCUCAGAGUAAA
CC-(dTdT)-30. LDH-B siRNA sense sequence: 50-ACUUAAU
CCAAUAGCCCAG-(dTdT)-30. SiRNAs were provided by
Dharmacon and applied at between 100 and 200 nM using
Oligofectamine (Invitrogen). Mock cells were transfected
with Oligofectamine alone. Flag-tagged AROS [42] was
transfected using lipofectamine reagent and cells grown for
24 h (Invitrogen).
5.2. Whole cell analysis
Representative cell phenotypes were recorded using phase
contrast microscopy (Olympus). Annexin V positive and pro-
pidium iodide negative staining identified early apoptotic
cells by flow cytometry (Roche, Beckton–Dickinson). Thepercentage of apoptotic cells were adjusted relative to mock
transfection set to 1. n  2 and error bars represent standard
deviation. Degrees of significance were calculated using
paired two-tailed Student’s t-tests. Data are representative
of three biological replicates.5.3. Quantification of mRNA
Total RNAwas purified by the RNeasy protocol (Qiagen) and
used in qRT-PCR with primers for Lamin AC and SIRT1 pre-
viously published [50]. AROS forward primer: 50-GGAAGA
CGAAGGCAATTCAGGC-30 and reverse primer: 50-TCCT
CGGTGAACACGGTGCC-30. n  3 and error bars represent
standard deviation. P-values were calculated using paired
two-tailed Student’s t-tests.5.4. SDS–PAGE and immunoblotting
Cells were lysed (10 mM Tris at pH 8.0, 140 mM NaCl, 2 mM
CaCl2, 0.5% v/v NP-40, 1 protease inhibitor cocktail (Roche)
and 5 U ml21 micrococcal nuclease), and the protein quantity
assayed by the Pierce bicinchoninic acid method. Lysates
were denatured in Laemmli’s sample buffer and equivalent
protein by mass analysed by SDS–PAGE. Nitrocellulose mem-
branes were pre-blocked for 1 h then incubated in primary
antibody overnight at 48C. Antibodies for western blotting
were provided by Santa Cruz (SIRT1, p53, Lamin AC), Alexis
(AROS), Epitomics (acetyl-p53 K382), Sigma (Flag) and
Millipore (b-actin) and were detected by HRP-conjugated
secondary antibody (Dako) and POD reagent (Roche). Densito-
metry was carried out using the open access IMAGEJ software
(National Institute of Health).
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